Atilotrelvir/Ritonavir

阿泰特韦/利托那韦

Report date: 2026/02/04 17:20:17
NME

Base Information

Drug NameAtilotrelvir/Ritonavir
Drug Alias NameGST-HG171/Ritonavir泰阿特韦/利托那韦泰中定
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitorsHuman immunodeficiency virus type 1 protease inhibitors
TargetsSARS-CoV-2-3C-like-proteinaseHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2023/11/23
Country/TerritoryMacauMainland China
CombinationsYes AtilotrelvirRitonavir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFujian Guangsheng Zhonglin Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Guangsheng Zhonglin Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A